Advanced search
1 file | 718.27 KB

Suppression of Myc oncogenic activity by nucleostemin haploinsufficiency

(2012) ONCOGENE. 31(28). p.3311-3321
Author
Organization
Abstract
Nucleostemin (NS), a nucleolar GTPase, is highly expressed in stem/progenitor cells and in most cancer cells. However, little is known about the regulation of its expression. Here, we identify the NS gene as a novel direct transcriptional target of the c-Myc oncoprotein. We show that Myc overexpression enhances NS transcription in cultured cells and in pre-neoplastic B cells from El-myc transgenic mice. Consistent with NS being downstream of Myc, NS expression parallels that of Myc in a large panel of human cancer cell lines. Using chromatin immunoprecipitation we show that c-Myc binds to a well-conserved E-box in the NS promoter. Critically, we show NS haploinsufficiency profoundly delays Myc-induced cancer formation in vivo. NS+/- El-myc transgenic mice have much slower rates of B-cell lymphoma development, with life spans twice that of their wild-type littermates. Moreover, we demonstrate that NS is essential for the proliferation of Myc-overexpressing cells in cultured cells and in vivo: impaired lymphoma development was associated with a drastic decrease of c-Myc-induced proliferation of pre-tumoural B cells. Finally, we provide evidence that in cell culture NS controls cell proliferation independently of p53 and that NS haploinsufficiency significantly delays lymphomagenesis in p53-deficient mice. Together these data indicate that NS functions downstream of Myc as a rate-limiting regulator of cell proliferation and transformation, independently from its putative role within the p53 pathway. Targeting NS is therefore expected to compromise early tumour development irrespectively of the p53 status.
Keywords
lymphoma, p53, c-Myc, nucleostemin, transgenic mice, TARGETED HOMOLOGOUS RECOMBINATION, RIBOSOMAL-PROTEIN L23, CELL-CYCLE ARREST, C-MYC, STEM-CELLS, IN-VIVO, GENE-EXPRESSION, DNA-DAMAGE, TRANSCRIPTIONAL REGULATION, INDUCED LYMPHOMAGENESIS

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 718.27 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Zwolinska, Aleksandra, A Heagle Whiting, Chantal Beekman, JM Sedivy, and Jean-Christophe Marine. 2012. “Suppression of Myc Oncogenic Activity by Nucleostemin Haploinsufficiency.” Oncogene 31 (28): 3311–3321.
APA
Zwolinska, A., Whiting, A. H., Beekman, C., Sedivy, J., & Marine, J.-C. (2012). Suppression of Myc oncogenic activity by nucleostemin haploinsufficiency. ONCOGENE, 31(28), 3311–3321.
Vancouver
1.
Zwolinska A, Whiting AH, Beekman C, Sedivy J, Marine J-C. Suppression of Myc oncogenic activity by nucleostemin haploinsufficiency. ONCOGENE. 2012;31(28):3311–21.
MLA
Zwolinska, Aleksandra, A Heagle Whiting, Chantal Beekman, et al. “Suppression of Myc Oncogenic Activity by Nucleostemin Haploinsufficiency.” ONCOGENE 31.28 (2012): 3311–3321. Print.
@article{2984529,
  abstract     = {Nucleostemin (NS), a nucleolar GTPase, is highly expressed in stem/progenitor cells and in most cancer cells. However, little is known about the regulation of its expression. Here, we identify the NS gene as a novel direct transcriptional target of the c-Myc oncoprotein. We show that Myc overexpression enhances NS transcription in cultured cells and in pre-neoplastic B cells from El-myc transgenic mice. Consistent with NS being downstream of Myc, NS expression parallels that of Myc in a large panel of human cancer cell lines. Using chromatin immunoprecipitation we show that c-Myc binds to a well-conserved E-box in the NS promoter. Critically, we show NS haploinsufficiency profoundly delays Myc-induced cancer formation in vivo. NS+/- El-myc transgenic mice have much slower rates of B-cell lymphoma development, with life spans twice that of their wild-type littermates. Moreover, we demonstrate that NS is essential for the proliferation of Myc-overexpressing cells in cultured cells and in vivo: impaired lymphoma development was associated with a drastic decrease of c-Myc-induced proliferation of pre-tumoural B cells. Finally, we provide evidence that in cell culture NS controls cell proliferation independently of p53 and that NS haploinsufficiency significantly delays lymphomagenesis in p53-deficient mice. Together these data indicate that NS functions downstream of Myc as a rate-limiting regulator of cell proliferation and transformation, independently from its putative role within the p53 pathway. Targeting NS is therefore expected to compromise early tumour development irrespectively of the p53 status.},
  author       = {Zwolinska, Aleksandra and Whiting, A Heagle and Beekman, Chantal and Sedivy, JM and Marine, Jean-Christophe},
  issn         = {0950-9232},
  journal      = {ONCOGENE},
  language     = {eng},
  number       = {28},
  pages        = {3311--3321},
  title        = {Suppression of Myc oncogenic activity by nucleostemin haploinsufficiency},
  url          = {http://dx.doi.org/10.1038/onc.2011.507},
  volume       = {31},
  year         = {2012},
}

Altmetric
View in Altmetric
Web of Science
Times cited: